Table 3.

Unadjusted and adjusted regression models of maternal complications and perinatal outcomes

	Crude OR/β (95% CI)	Model 1 OR/β (95% CI)	Model 2 OR/β (95% CI)
GDM
HRT	Ref.	Ref.
HMG	1.19 (0.91–1.57)	1.20 (0.89–1.61)	_
HMG + LE	1.33 (0.91–1.93)	1.20 (0.79–1.81)
Ptrend	–	0.221
HDP
HRT	Ref.	Ref.	_
HMG	0.79 (0.58–1.06)	0.72 (0.52–0.99) *
HMG + LE	0.58 (0.36–0.95)	0.59 (0.35–0.98) *
Ptrend	–	0.031*
Gestational age (weeks)
HRT	Ref.	Ref.	Ref.
HMG	(-0.14–0.21)	-0.85 (-0.14–0.20)	(-0.17–0.18)
HMG + LE	-0.03 (-0.40–0.09)	0.27 (-0.38–0.14)	-0.23 (-0.39–0.11)
Ptrend	–	0.541	0.921
LGA
HRT	Ref.	Ref.	Ref.
HMG	0.81 (0.68–0.96) *	0.76 (0.63–0.91) *	0.74 (0.62–0.89) *
HMG + LE	0.67 (0.52–0.87) *	0.64 (0.48–0.84) *	0.62 (0.47–0.82) *
Ptrend	–	0.001*	<0.001*
Preterm birth
HRT	Ref.	Ref.	Ref.
HMG + LE	1.11 (0.75–1.63)	1.04 (0.69–1.58)	1.11 (0.73–1.69)
HMG	0.97 (0.73–1.28)	1.00(0.74–1.35)	1.04 (0.77–1.42)
Ptrend	–	0.998	0.753

OR odds ratio, CI confidence interval, HMG human menopausal gonadotropin, LE letrozole, HRT hormone replacement therapy, GDM gestational diabetes mellitus, HDP hypertensive disorders of pregnancy, LGA large for gestational age, Ref. reference

Model 1, adjusted for maternal age, body mass index, type of infertility, insemination method, number of embryos transferred, basal serum estradiol, basal serum T₀, endometrial thickness, AFC, and LH/FSH ratio, parity Model 2, adjusted for Model 1 + GDM, and HDP

*p-value < 0.05 was considered as statistically significant